X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Cell-Energy Activity In Organs, Tissues By New MRI Method

    Cell-Energy Activity In Organs, Tissues By New MRI Method

    GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing

    Australia Sepsis Study To Aid In New Antibiotic Discovery

    FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

    COVID-19 Hospitalisation Dips Using Monoclonal Antibodies

    Regulatory Actions Needed For Gaps In Cancer Drug Info

    A Fund Boost For World-First Nervous System Transplant Study

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Cell-Energy Activity In Organs, Tissues By New MRI Method

    Cell-Energy Activity In Organs, Tissues By New MRI Method

    GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing

    Australia Sepsis Study To Aid In New Antibiotic Discovery

    FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

    COVID-19 Hospitalisation Dips Using Monoclonal Antibodies

    Regulatory Actions Needed For Gaps In Cancer Drug Info

    A Fund Boost For World-First Nervous System Transplant Study

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

COVID-19 Hospitalisation Dips Using Monoclonal Antibodies

Content Team by Content Team
5th April 2023
in News, Research & Development
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

A study has gone on to find that monoclonal antibodies (mAbs) decreased the risk of hospitalisation or even death by 39% if given within two days to people who are tested positive for COVID-19.

The research compared the patients who were administered this treatment to those who were eligible but did not receive it. Notably, the immunocompromised patients got to experience a further reduced risk, as per the researchers. The risk infection level was determined at a period of 28 days.

The researchers from the University of Pittsburgh Medical Centre, under the trial, evaluated around 2571 patients who got treated with monoclonal antibodies. The details of these patients were then matched with the data from 5131 eligible COVID-19 patients who did not get the treatment. Notably, single-dose intravenous mAb treatment doses were administered with either sotrovimab, bamlanivavimab, bebtelovimab, bamlanivimab-etesevimab, intravenous, or imdevimab. The inferences pointed to the total risk when it came to hospitalisation or death at 28 days, which stood at 4.6% in the patients who were treated as compared to 7.6% in non-treated and controlled patients.

It is well to note that between 2020 and 2022, the US FDA granted emergency use authorization (EUA) to five varied COVID-19 monoclonal antibody treatments. All these treatments ultimately showed a reduction in COVID-19 viral load. Subsequently, they also showed their ability to decrease hospitalisation and death rates in some of the at-risk patients as well.

These authorised treatments somehow have either been suspended or revoked by the FDA ever since, because of the in vitro evidence that involves loss of efficacy surrounding novel COVID-19 variants. That said, this action was taken without the availability of any randomised trial or even any real-world data.

In the current study, the growing real-world efficacy of an early mAb treatment was determined for outpatients suffering from COVID-19 who were treated for almost 2 years. As per the authors, the results indicate that all across the pandemic, early treatment using monoclonal antibodies significantly lowered the severity of COVID-19. These findings are indeed very important since, as of date, there aren’t any FDA-approved monoclonal antibody treatments when it comes to COVID-19 outpatients, the authors emphasise.

Previous Post

AI Assesses The Enzyme Functions Finer Than Leading Tools

Next Post

Australia Sepsis Study To Aid In New Antibiotic Discovery

Related Posts

Cell-Energy Activity In Organs, Tissues By New MRI Method
News

Cell-Energy Activity In Organs, Tissues By New MRI Method

5th April 2023
TrakCel and WindMIL Therapeutics partner on cell therapy supply chain management and orchestration platform
News

Seamlessness In Patient Engagement Through eConsent Trial

5th April 2023
GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing
Drug Development

Australia Sepsis Study To Aid In New Antibiotic Discovery

5th April 2023
AI Assesses The Enzyme Functions Finer Than Leading Tools
IPR Data Management

AI Assesses The Enzyme Functions Finer Than Leading Tools

4th April 2023
FDA Approvals

Regulatory Actions Needed For Gaps In Cancer Drug Info

4th April 2023
News

A Fund Boost For World-First Nervous System Transplant Study

4th April 2023
Next Post
GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing

Australia Sepsis Study To Aid In New Antibiotic Discovery

Latest News

Cell-Energy Activity In Organs, Tissues By New MRI Method
News

Cell-Energy Activity In Organs, Tissues By New MRI Method

5th April 2023
TrakCel and WindMIL Therapeutics partner on cell therapy supply chain management and orchestration platform
News

Seamlessness In Patient Engagement Through eConsent Trial

5th April 2023
GE Healthcare Launches Viral Vector Based Gene Therapy Manufacturing
Drug Development

Australia Sepsis Study To Aid In New Antibiotic Discovery

5th April 2023
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
News

COVID-19 Hospitalisation Dips Using Monoclonal Antibodies

5th April 2023
AI Assesses The Enzyme Functions Finer Than Leading Tools
IPR Data Management

AI Assesses The Enzyme Functions Finer Than Leading Tools

4th April 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In